Toch wat leuker geschetst dan in broodnuchter hollands:
Dit is een origineel bericht van PR Newswire
LEIDEN, The Netherlands, October 26, 2017 /PRNewswire/ --
Strong increase in revenues boosts operating profitability and positive cash flow
Strong outlook with increasing revenues expected for remainder of 2017
Pharming Group N.V. ("Pharming" or "the Company") , the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.
Financial highlights
- Revenues for the nine months to 30 September increased to EUR56.7 million (2016
EUR8.7 million), with Q3 alone EUR25.9 million ($30.5 million, up 73% on Q2 2017), due
to strong growth in US and EU sales
- Q3 operating profit up to EUR8.5 million compared with a loss of EUR3.2 million in Q3
2016
- Q3 net result improved to EUR7.5 million loss compared with a loss of EUR24.5 million
in Q2
- Positive cashflows during Q3 increased the cash position to EUR38.6 million from
EUR25.2 million at June 30 2017 (and EUR17.0 million at 30 September 2016)
Operational highlights during the third quarter
- On September 11, following the conclusion of the End-of-Phase 2 interactions with
the US Food and Drug Administration (FDA), Pharming announced that it will submit a
supplemental Biologics License Application (sBLA) to the FDA for review in Q4 of this
year for prophylaxis of angioedema attacks in adolescent and adult patients with
hereditary angioedema (HAE) as an expanded indication for RUCONEST(R) [Recombinant
Human C1 Esterase Inhibitor/ conestat alfa]
- On September 26, the Company, in association with HAEi (the international umbrella
organization for the world's HAE patient groups), announced the appointment of
Inceptua Medicines Access as their new distribution partner for the "HAEi Global
Access Program" (HAEi GAP) enabling patients in all countries where Pharming's product
RUCONEST(R) is not commercially available to gain access to the drug through an
ethical and regulatory-compliant mechanism
- Positive results were obtained from a Phase II clinical trial investigating the use of
RUCONEST(R) for the treatment of HAE attacks in children
Post period highlights
- The RUCONEST(R) US Biologics License Application has been transferred from Valeant
Pharmaceuticals International, Inc. ("Valeant") to Pharming, following
the acquisition of the North American commercial rights to the product in December
2016